ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $4,266,350.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 55,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $77.57, for a total value of $4,266,350.00. Following the sale, the chief executive officer owned 349,889 shares in the company, valued at approximately $27,140,889.73. This represents a 13.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

ANI Pharmaceuticals Trading Down 2.0%

Shares of ANI Pharmaceuticals stock opened at $78.01 on Friday. ANI Pharmaceuticals, Inc. has a 12-month low of $56.71 and a 12-month high of $99.50. The stock has a market cap of $1.77 billion, a P/E ratio of 19.75 and a beta of 0.46. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The business’s 50 day moving average is $77.29 and its 200-day moving average is $80.48.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. During the same quarter in the prior year, the business posted $1.70 EPS. The business’s revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts predict that ANI Pharmaceuticals, Inc. will post 7.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Zacks Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 15th. Guggenheim upped their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Finally, Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $107.33.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. KBC Group NV acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. Advisors Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. Hantz Financial Services Inc. increased its holdings in shares of ANI Pharmaceuticals by 202.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after acquiring an additional 237 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of ANI Pharmaceuticals during the 4th quarter worth approximately $48,000. Finally, State of Wyoming acquired a new position in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $50,000. 76.05% of the stock is owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.